-
Australian Katie Perry wins trademark spat against singer Katy Perry
-
CEO of Brazil's Nubank on pending US market entry, Trump, AI: interview
-
Bolsonaro brand fuels Flavio's rise in Brazil election polls
-
Kast: Who is Chile's new hard-right president?
-
Chile's Kast, most right-wing president since Pinochet, takes office
-
China sprint race presents 'huge challenge' in F1's new era
-
Bangladesh sari weaving tradition hangs by a thread
-
Alleged Rihanna mansion shooter charged with attempted murder
-
Microsoft urges Pentagon pause blacklisting Anthropic
-
Harvey Weinstein says prison is 'hell'
-
'Put our faith in God': Tehran residents adapt to wartime
-
Caviar, truffle and chicken pot pies: what Hollywood will eat at the Oscars
-
US says wouldn't be 'happy' if Russia giving Iran intel
-
US targets Iran mine-laying as war causes oil market havoc
-
Yamal denies Newcastle, Liverpool lose and Atletico thrash Spurs in Champions League
-
Olise could be world great, says Bayern coach Kompany
-
Two more members of Iran women's football team claim asylum in Australia
-
'Incredible situation': Spurs coach Tudor on subbing Kinsky after errors
-
Police say deadly Swiss bus fire could be deliberate
-
Bayern on verge of Champions League quarters after hitting Atalanta for six
-
Griezmann dreaming big at Atletico after Spurs rout
-
Howe sees 'hope' for Newcastle despite blow of Barcelona equaliser
-
Dassault pitches latest private jet against US, Canadian rivals
-
Fresh Israeli strikes hit Lebanon after evacuation warnings
-
Yamal penalty rescues Barca from defeat at Newcastle
-
Bayern on verge of Champions League quarters after smashing six past Atalanta
-
Louis Vuitton takes Paris fashion week on mountain ride
-
Slot frustrated by sloppy Liverpool in Galatasaray defeat
-
Atletico capitalise on Tottenham's Champions League nightmare
-
Fils surprises Auger-Aliassime to set Zverev quarter-final clash
-
Will Trump blink on Iran as pressure mounts?
-
Mideast tanker escort: high-risk mission for US Navy
-
Oil prices dive as IEA eyes emergency release with Hormuz Strait in focus
-
Iran not seeking ceasefire as Trump steps up threats
-
US satellite firm extends Middle East image delay
-
Spurs sub goalkeeper Kinsky after two huge errors in 17 minutes
-
Oil plunges, stocks mostly rise as Trump says Iran war over 'very soon'
-
Sabalenka powers past Osaka into Indian Wells quarter-finals
-
Trump team's Iran war rhetoric fuels backlash
-
French Paralympian Bauchet's golden end to a 'tough' day
-
Liverpool rocked by Galatasaray defeat in Champions League last 16 first leg
-
Liverpool rocked by Galatasaray defeat in last 16 first leg
-
White House says US Navy has not escorted tanker through Strait of Hormuz
-
Rosenior says Club World Cup victory irrelevant as Chelsea and PSG clash again
-
'Don't use that phrase': Arteta shuts down Arsenal quadruple talk
-
Shifting sands? Trump and his elastic timeline for Iran war
-
Ukraine says hit 'key' Russian military factory in missile strike
-
Will Trump 'TACO' on Iran?
-
Family of Canada mass shooting victim sues OpenAI
-
Blasts rock Tehran as US says strikes to intensify
Moderna sues Pfizer, BioNTech for Covid-19 vaccine patent infringement
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"This groundbreaking technology was critical to the development of Moderna's own mRNA Covid-19 vaccine, Spikevax. Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna added.
US-based Pfizer said it has not received the lawsuit and declined to speak further, while Germany's BioNTech did not immediately reply to a request for comment.
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are both safe and effective.
The lawsuits -- to be filed in filed Friday both in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on coronaviruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
G.Schulte--BTB